MPM
AVIR icon

Meritage Portfolio Management’s Atea Pharmaceuticals AVIR Stock Holding History

Meritage Portfolio Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-21,476
Closed -$72K – 342
2023
Q1 		$72K Sell
21,476
-738
-3% -$2.99K 0.01% 309
2022
Q4 		$107K Buy
22,214
+779
+4% +$3.94K 0.01% 306
2022
Q3 		$122K Buy
21,435
+76
+0.4% +$582 0.01% 297
2022
Q2 		$152K Buy
21,359
+591
+3% +$4.04K 0.01% 299
2022
Q1 		$150K Buy
20,768
+2,635
+15% +$17.9K 0.01% 332
2021
Q4 		$162K Buy
+18,133
New +$283K 0.01% 331

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meritage Portfolio Management's AVIR Position: Q2 2023 in Review

Meritage Portfolio Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 21,476 shares — an estimated $72K sold.

Meritage Portfolio Management first reported a position in AVIR in Q4 2021 and held it in 6 quarters. The position peaked at $162K in Q4 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Meritage Portfolio Management reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Meritage Portfolio Management sold 21,476 Atea Pharmaceuticals shares in Q2 2023, an estimated $72K.
  • Meritage Portfolio Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Meritage Portfolio Management's Atea Pharmaceuticals position peaked at $162K in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Meritage Portfolio Management's 13F filing for Q2 2023, filed 31 Jul 2023.